Gene Shigekawa, Managing Partner of Maz World Ltd
Biotech company Maz World specialises in the commercialization of a revolutionary technology which uses ostrich antibodies to ward off influenza. Maz World joined Hong Kong Science Park in 2017. The company’s managing partner Gene Shigekawa has found Hong Kong is not just a financial centre but also has a deep pool of bio-technology talents. He believes the city has huge potential to become a biotechnology hub.